EMEA-000402-PIP02-11-M05

Key facts

Invented name
Vimpat
Active substance
lacosamide
Therapeutic area
Neurology
Decision number
P/0001/2018
PIP number
EMEA-000402-PIP02-11-M05
Pharmaceutical form(s)
  • Film-coated tablet
  • Syrup
  • Solution for infusion
Condition(s) / indication(s)
Treatment of epilepsy with partial-onset seizures
Route(s) of administration
  • Oral use
  • Intravenous use
Contact for public enquiries
UCB Pharma S.A.

Tel. +44 1753677251
E-mail: kenneth.johnson@ucb.com

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000402-PIP02-11-M05
Compliance opinion date
27/07/2018
Compliance outcome
positive

Decision

How useful was this page?

Add your rating
Average
1 rating